Biostatistician
University of Washington
Mark Warden is a PhD candidate in the Epidemiology department at the University of Washington (UW) in Seattle, working at the Cystic Fibrosis Therapeutics Development Network Coordinating Center (CF TDNCC) under the mentorship of Dr. Nicole Hamblett and Dr. Amalia Magaret. He has worked on the CHEC-SC, Goal, and Prospect studies with a focus on the effect of CFTR modulators on population level health. His research has focused on clinical trial methods for the development of new CF therapeutics within a population that highly utilizes CFTR modulators. Specifically, the focus is on continuing development of therapeutics in those not yet eligible for CFTR modulators and other populations for which traditional randomized controlled trials may not be logisticially feasible. His interests also include utilization of real world data and the generation of real world evidence under 2018 FDA framework. Prior to joining UW, Mark recieved his master's degree in biostatistics from Washingotn university in St. Louis.